Pulmonary Arterial Hypertension (PAH) - NATIONWIDE (Clinical Trial 9527)

This clinical trial is not currently recruiting participants. To find active clinical trials similar to this one please visit Clinical Trials Search. To be notified of new clinical trials as they become available visit Free Member Signup.

Study summary

FREEDOM: Studies for patients with pulmonary arterial hypertension

About the studies
Pulmonary arterial hypertension (PAH) is a rare and debilitating condition that causes high blood pressure in lung blood vessels. Symptoms may include shortness of breath, tiredness, chest pain, and a rapid heartbeat. As the disease progresses, it can lead to heart failure and death. Thanks to ongoing clinical research, management of the disease has improved over the years.

The FREEDOM studies are Phase III clinical research studies investigating the safety and efficacy of an oral prostanoid, UT-15C (treprostinil diethanolamine) sustained-release tablets, in patients with PAH. UT-15C SR may offer an additional treatment option to patients with PAH, as it could be the first orally available sustained-release prostanoid of its kind.

About the study drug
Currently available prostanoid therapies are administered by inhalation or given to patients through an IV or subcutaneous infusion, which may be difficult for some patients to manage. The drug being evaluated in the FREEDOM studies, UT-15C SR, is an oral, sustained-release prostanoid that may help in the treatment of PAH. The sustained-release formulation of the drug increases the time the drug is available to the body, which may result in less frequent dosing.

Who can participate?
You may be eligible if you:

Are 12–75 years old
Have a confirmed diagnosis of PAH

What does the study involve?
Eligible study participants will be asked to:

Provide informed consent
Attend study visits
Receive the study drug orally
Undergo study-related physical exams
Speak with the study staff about your health and wellbeing

Participants will receive the study drug or placebo and may be eligible to continue to receive the study medication in an open-label extension study. Participants in the FREEDOM studies will be reimbursed for all reasonable travel expenses, and study coordinators will assist individuals with travel arrangements to ensure that all participants are able to safely and conveniently travel to a PAH study site.

Study is available at

This study is being conducted NATIONWIDE! To find clinics conducting this study near you please use search feature below.

Study Locations

ClinicalConnection.com is a resource that provides information on clinical trials and other research opportunities worldwide.

ClinicalConnection.com does not conduct or endorse this research. Please consult your physician before participating.

Latest Blog Posts

Useful Links

Contact Us

75 Second Ave, Suite 605
Needham, MA 02494
1-800-887-0639
info@clinicalconnection.com
Click here to contact us

Services for Research Sites

National Recruitment Services

News And Information